SusanM.O'BrienMD

Oncology • Orange, CA

Hematologic Oncology

Associate Director for Clinical Sciences, Chao Family Comprehensive Cancer Center, UCI Health

Join to view full profile

Dr. O'Brien is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Brien's full profile

Already have an account?

Office
101 The City Drive South
Bldg 23 RM 403
Orange, CA 92868
Phone+1 714-456-8000

Fax+1 714-456-3810

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1987
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1980 - 1983
Rutgers New Jersey Medical SchoolClass of 1980

Certifications & Licensure

CA State Medical License 2018 - 2026
TX State Medical License 1987 - 2024
NJ State Medical License 1983 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Giants of Cancer Care: Leukemia MJH Life Sciences, 2021
America's Top Doctors for Cancer Castle Connolly, 2005-2019
America's Top Doctors Castle Connolly, 2003-2019
Top Doctors:SE Texas Castle Connolly, 2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 1994 Sep 01
Completed
Phase 2
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Start of enrollment: 2006 Aug 01
Completed
Phase 2
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2007 Feb 01
Completed
Phase 2
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia Start of enrollment: 2007 May 01
Completed
Phase 2
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2008 Jan 01
Completed
Phase 2
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma Start of enrollment: 2002 Aug 01
Completed
Phase 2
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2011 Oct 05
Active, not recruiting
Phase 2
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies Start of enrollment: 2013 Dec 13
Completed
Phase 1
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2013 Dec 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Lessons learned from the CAPTIVATE trial of ibrutinib plus venetoclax in CLL.
Susan O'Brien
Clinical Advances in Hematology & Oncology. 2021-10-01
12 citations
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propen...
Koji Sasaki, Hagop M. Kantarjian, Kiyomi Morita, Nicholas J. Short, Marina Konopleva
Cancer. 2021-09-15
24 citations
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.
Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio
Blood. 2021-08-18

Abstracts/Posters

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Susan O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Susan M. o'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Susan M. O'Brien, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Expert Discussion and Guidance on New Advances, Clinical Opportunities, and Current Challenges in Treating Adults with Ph-Negative Acute Lymphoblastic Leukemia
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Discussing Treatment of CLL in the Era of Novel Therapeutic AgentsDecember 3rd, 2019
Improving Outcomes in Older Patients with Newly Diagnosed ALLMay 9th, 2019
T2D'S Tie to Pancreatic Ca: Oncotherapy Network & Cancer NetworkFebruary 14th, 2017
Join now to see all